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INTRODUCTION
Studies assessing the impact of total comorbidity burden on
outcomes of COVID-19 in age- and sex-controlled analyses
are lacking. Previous studies identified the following single
comorbidities as risk factors for poor COVID-19 outcomes:
coronary heart disease, congestive heart failure, cardiac ar-
rhythmia, chronic obstructive pulmonary disease, cancer, and
diabetes.1 In this nationwide study of Danish COVID-19
patients, we investigated if Charlson Comorbidity Index Score
(CCIS) was associated with the risk of severe outcome and
death.
METHODS
In Denmark, all permanent residents are provided a unique
personal identification number enabling cross-linkage of com-
plete nationwide healthcare registries. We included all patients
diagnosed with COVID-19 until May 3, 2020, using informa-
tion from the Danish Civil Registration System (holding de-
mographic data) and the Danish National Patient Registry
(holding data on all hospital contacts classified according to
ICD-10 codes). Data on comorbidities 10 years prior to the
date of COVID-19 were identified to calculate the exposure of
interest: CCIS of 0, 1–2, 3–4, and > 4.2 Outcomes of interest
were (1) a composite of death, diagnosis of severe acute
respiratory syndrome (ICD-10: DB972A), intensive care unit
(ICU) admission, and (2) death. Logistic regression models
adjusted for sex and age as a continuous variable were
employed to associate CCIS 1–2, CCIS 3–4, and CCIS > 4
with odds of outcomes. The models were used to estimate the
absolute risk of both outcomes according to CCIS groups
across ages 40–85 for both sexes.
RESULTS
A total of 4480 patients were diagnosed with COVID-19, of
which 2911 (65.0%), 1112 (24.8%), 288 (6.4%), and 169
(3.8%) had a CCIS of 0, 1–2, 3–4, and > 4, respectively
(Table 1). The median age of the total population was 55
years, with the oldest patients in the CCIS 3–4 group (78
years).
Overall, 17.8% had severe outcome and 9.3% died. In the
CCIS 0 group, 265 (9.1%) had severe outcome and 77 (2.6%)
died. In the CCIS 1–2, 3–4, and > 4 groups, 330 (29.7%), 123
(42.7%), and 80 (47.3%) had severe outcome and 197
(17.7%), 85 (29.5%), and 58 (34.3%) died, respectively.
The odds of severe COVID-19 were significantly increased
in CCIS 1–2 (odds ratio [OR], 1.76 [95% CI, 1.43 to 2.16]),
CCIS 3-4 (OR, 2.36 [95% CI, 1.74 to 3.18]) and CCIS > 4
(OR, 2.67 [95% CI, 1.87 to 3.81]) compared with those in
CCIS 0. The odds of death were significantly increased for
CCIS 1–2 (OR, 2.13 [95% CI, 1.57 to 2.90]), CCIS 3–4 (OR,
3.00 [95% CI, 2.06 to 4.38]), and CCIS > 4 (OR, 3.85 [95%
CI, 2.51 to 5.90]) compared with those for CCIS 0.
The estimated absolute risks of severe COVID-19 and death
were increased for CCIS 1–2, 3–4, and > 4 compared with
those for CCIS 0 across ages and sexes (Fig. 1).
DISCUSSION
A Charlson Comorbidity Index Score above 0 was associated
with an increased risk of severe COVID-19 and death when
controlled for age and sex. This expands upon previous find-
ings of individual comorbidities as independent risk factors for
poor COVID-19 outcomes.1 Our findings may inform epi-
demic modeling, public health, and clinical decisions regard-
ing the management of the COVID-19 pandemic.
A limitation of this study was that not all patients had
reached a study outcome or recovered by the end of the study
period. Additionally, it was not possible to associate the indi-
vidual comorbidities constituting the CCIS with the outcomes
due to lack of power. The Danish healthcare system is free
with universal access and its ICU capacity was not exceeded
during the study period,3 which must be considered when
interpreting our findings. More studies are needed to assess
the impact of comorbidity combinations on COVID-19 out-
comes and to determine if other validated comorbidity scores
can predict poor outcomes of COVID-19.
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Table 1 Baseline Characteristics
CCIS 0 (n = 2911) CCIS 1–2 (n = 1112) CCIS 3–4 (n = 288) CCIS > 4 (n = 169) Total (n = 4480)
Male 1326 (45.6) 559 (50.3) 149 (51.7) 110 (65.1) 2,144 (47.9)
Age [IQR] 47 [35, 58] 71 [56, 81] 78 [67, 85] 77 [69, 83] 55 [41, 72]
CCIS [IQR] 0 [0, 0] 1 [1, 2] 3 [3, 4] 6 [5, 8] 0 [0, 1]
Comorbidities, no. (%)
Myocardial infarction 0 (0.0) 65 (5.8) 40 (13.9) 44 (26.0) 149 (3.3)
Heart failure 0 (0.0) 77 (6.9) 66 (22.9) 55 (32.5) 198 (4.4)
Cerebrovascular disease 0 (0.0) 171 (15.4) 85 (29.5) 50 (29.6) 306 (6.8)
Peripheral vascular disease 0 (0.0) 63 (5.7) 52 (18.1) 45 (26.6) 160 (3.6)
Diabetes with complications 0 (0.0) 38 (3.4) 60 (20.8) 62 (36.7) 160 (3.6)
Diabetes 0 (0.0) 206 (18.5) 102 (35.4) 88 (52.1) 396 (8.8)
Dementia 0 (0.0) 100 (9.0) 36 (12.5) 20 (11.8) 156 (3.5)
Hemi- or paraplegia 0 (0.0) 10 (0.9) 5 (1.7) 6 (3.6) 21 (0.5)
Rheumatic disease 0 (0.0) 71 (6.4) 34 (11.8) 13 (7.7) 118 (2.6)
Peptic ulcer 0 (0.0) 24 (2.2) 19 (6.6) 18 (10.7) 61 (1.4)
COPD 0 (0.0) 306 (27.5) 93 (32.3) 66 (39.1) 465 (10.4)
Chronic renal disease 0 (0.0) 30 (2.7) 57 (19.8) 67 (39.6) 154 (3.4)
Mild liver disease 0 (0.0) 35 (3.1) 11 (3.8) 16 (9.5) 62 (1.4)
Severe liver disease 0 (0.0) 0 (0.0) 8 (2.8) 10 (5.9) 18 (0.4)
Cancer 0 (0.0) 156 (14.0) 106 (36.8) 86 (50.9) 348 (7.8)
Metastatic cancer 0 (0.0) 0 (0.0) 0 (0.0) 49 (29.0) 49 (1.1)
HIV/AIDS 0 (0.0) 0 (0.0) 0 (0.0) * *
CCIS, Charlson comorbidity index score; COPD, chronic obstructive pulmonary disease; IQR, interquartile range. *Low number of observations,
blanked to ensure patient anonymity
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Figure 1 Estimated risks of severe outcome and death according to sex, age, and Charlson Comorbidity Index Score (CCIS).
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